
X
Axovant pushes on with Parkinson’s gene therapy, despite investor cynicism
https://pharmaphorum.com/news/axovant-pushes-on-with-parkinsons-gene-therapy/
Last month the biotech Axovant was rocked by the failure of its star drug intepirdine in Alzheimer’s disease – and the fall-out is still being felt, with CEO David Hung deciding to walk out.
Axovant misreports trial results, Lundbeck Alzheimer’s drug fails
Intepirdine seemed to make symptoms worse in Lewy body disease
Shares fall off a cliff after intepirdine fails to produce results.